FDA oversight of laboratory‐developed tests will facilitate adoption of pharmacogenetic testing into routine clinical care

Publisher： John Wiley & Sons Inc

E-ISSN： 1552-4604|55|7|728-730

ISSN： 0091-2700

Source： JOURNAL OF CLINICAL PHARMACOLOGY (ELECTRONIC), Vol.55, Iss.7, 2015-07, pp. : 728-730

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

FDA's draft guidance on laboratory‐developed tests increases clinical and economic risk to adoption of pharmacogenetic testing

By  

JOURNAL OF CLINICAL PHARMACOLOGY (ELECTRONIC), Vol. 55, Iss. 7, 2015-07 ,pp. : 725-727

John Wiley & Sons Inc

Access to resources Recommend Favorite

US Food and Drug Administration regulatory oversight of laboratory‐developed tests: Commentary on the draft guidance

By  

CANCER CYTOPATHOLOGY, Vol. 123, Iss. 10, 2015-10 ,pp. : 573-575

John Wiley & Sons Inc

Access to resources Recommend Favorite

Laboratory testing of rivaroxaban in routine clinical practice: When, how, and which assays

By Lindhoff-Last Edelgard   Ansell Jack   Spiro Theodore   Samama Meyer Michel  

Annals of Medicine, Vol. 45, Iss. 5-6, 2013-09 ,pp. : 423-429

Informa Healthcare

Access to resources Recommend Favorite

Clinical pharmacy consultation for pharmacogenetic testing

By Shin Jaekyu   Kayser Steven R  

Personalized Medicine, Vol. 6, Iss. 2, 2009-03 ,pp. : 183-192

Future Medicine

Access to resources Recommend Favorite

Attitudes of Health Care Professionals Toward Pharmacogenetic Testing

By Zgheib Nathalie K.  

Molecular Diagnosis & Therapy, Vol. 15, Iss. 2, 2011-04 ,pp. : 115-122

Adis International

Access to resources Recommend Favorite